Search JRPMS

JRPMS Vol 3, No 3, September 2019, p.106-112

doi: 10.22540/JRPMS-03-106


Review Article

The relation of parathyroid hormone and hematologic parameters under erythropoetin administration in hemodialysis patients

Theodora Papachrysanthou1,2, Maria Aktsiali1,2, Ioannis Griveas3, Christos Andriopoulos1, Panagiotis Sitaras1, George I. Lambrou2,5

  1. Private Dialysis Unit “Nefroiatriki”, Athens, Greece
  2. Graduate Program “Metabolic Bones Diseases”, National and Kapodistrian University of Athens, Medical School, Athens, Greece
  3. 417 Veterans Army Administration Hospital of Athens, Athens, Greece
  4. National and Kapodistrian University of Athens, Medical School, Laboratory for the Research of Musculoskeletal Disorders, Athens, Greece
  5. First Department of Pediatrics, University of Athens, Choremeio Research Laboratory, National and Kapodistrian University of Athens, Athens, Greece

Keywords: Hemodialysis, End Stage Renal Disease, Erythropoetin, Parathyroid hormone, Hematologic parameters


Hemodialysis has been the principal therapeutic tool for End Stage Renal Disease (ESRD) for decades. ESRD patients are defined as those having Glomerular Filtration Rate (GFR) under 15 ml/min. Loss of renal function can result either as acute kidney failure or gradually, following the natural course of a vascular disease such as hypertension and Diabetes mellitus. Metabolic bone disease is a very common situation for the majority of patients with chronic renal disease due to severe imbalance in bone remodeling as well as mineral homeostasis. The aim of the present study was to investigate the relation of Erythropoetin (Epo) administration in ESRD patients with hematologic factors as well as parathyroid hormone (PTH) levels. A retrospective observational study was conducted in an outpatient Chronic Hemodialysis Unit between January 2015 and December 2016 (24 months). Patients with ESRD were recruited, who had received hemodialysis for at least twelve months. Several hematologic factors as well as PTH levels were evaluated in ESRD patients and the results were compared in order to find the effect of Epo administration on those factors. We have found that Epo significantly affects hematologic factors, but it marginally affects PTH levels. Our study has confirmed that Epo administration has beneficial effects to hematologic parameters, in ESRD patients, yet with marginal effect on PTH and thus its role in bone metabolism needs to be further investigated.